Inhibition of platelet function: Does it offer a chance of better cancer progression control?

Seminars in Thrombosis and Hemostasis

Volumn 33, Issue 7, 2007, Pages 712-721

  Sierko, Ewa ^a,b   Wojtukiewicz, Marek Z ^a,b  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b Regional Comprehensive Cancer Center in Bialystok   (Poland)

Author keywords

Angiogenesis; Cancer; Immune surveillance; Metastasis; Platelet inhibitors; Proteolysis

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANGIOGENESIS INHIBITOR; ARGINYLGLYCYLASPARTIC ACID; BENCYCLANE; CYPROHEPTADINE; DITAZOLE; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; GELATINASE A; GROWTH FACTOR; HEPARIN; LIPOXYGENASE INHIBITOR; LOW MOLECULAR WEIGHT HEPARIN; MONOCLONAL ANTIBODY 10E5; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEINASE ACTIVATED RECEPTOR 1; RHODOSTOMIN; RWJ 56110; SCH 79797; SNAKE VENOM; THROMBIN INHIBITOR; THROMBOPOIETIN; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRAPIDIL; TRIFLAVIN; TRIGRAMIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; UROKINASE RECEPTOR; VASCULOTROPIN;

ANGIOGENESIS; BLOOD CLOTTING; CANCER CELL; CANCER CONTROL; CANCER GROWTH; CANCER PATIENT; CELL INVASION; DISEASE ASSOCIATION; ENDOTHELIUM CELL; HUMAN; INHIBITION KINETICS; MEGAKARYOCYTE; METASTASIS; MICROPARTICLE ENZYME IMMUNOASSAY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN SECRETION; REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION; THROMBOCYTOSIS; THROMBOSIS; TUMOR CELL; TUMOR GROWTH;

ANTICOAGULANTS; BLOOD COAGULATION; BLOOD PLATELETS; DISEASE PROGRESSION; FIBRINOLYTIC AGENTS; HEMOSTASIS; HUMANS; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PARANEOPLASTIC SYNDROMES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; THROMBOCYTOSIS;

EID: 36348974088     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-991540     Document Type: Review

References (135)

1. Francis JL, Biggerstaff J, Amirkhosravi A. Hemostasis and malignancy. Semin Thromb Hemost 1998;24:93-109
2. Zacharski LR, Wojtukiewicz MZ, Costantini V, Ornstein DL, Memoli VA. Pathways of coagulation/fibrinolysis activation in malignancy. Semin Thromb Hemost 1992; 18:104-116
3. Rickles FR, Levine M, Edwards RL. Hemostatic alterations in cancer patients. Cancer Metastasis Rev 1992;11:237-248
4. Sierko E, Wojtukiewicz MZ. Platelets and angiogenesis in malignancy. Semin Thromb Hemost 2004;30:95-108
5. Uppenkamp M, Makarove E, Petrasch S, Brittinger G. Thrombopoietin serum concentration in patients with reactive and myeloproliferative thrombocytosis. Ann Hematol 1998;77:217-223
6. Kato N, Yasukawa K, Onozuka T, Kimura K. Paraneoplastic syndromes of leukocytosis, thrombocytosis, and hypercalcemia associated with squamous cell carcinoma. J Dermatol 1999;26:352-358
7. Estrov Z, Talpaz M, Mavlight G, et al. Elevated plasma thrombopoietic activity in patients with metastatic cancer-related thrombocytosis. Am J Med 1995;98:551-558
8. Gastl G, Plante M, Finstad CL, et al. High IL-6 levels in ascitic fluid correlate with reactive thrombocytosis in patients with epithelial ovarian cancer. Br J Haematol 1993;83:433-441
9. Suzuki A, Takahashi T, Nakamura K, et al. Thrombocytosis in patients with tumors producing colony-stimulating factor. Blood 1992;80:2052-2059
10. Raffi S, Shapiro F, Pettengeli R, et al. Human bone marrow microvascular endothelial cells support long-term proliferation and differentiation of myeloid and megakaryocytic progenitors. Blood 1995;86:3353-3363
11. Baj-Krzyworzeka M, Majka M, Pratico D, et al. Platelet-derived microparticles stimulate proliferation, survival, adhesion, and chemotaxis of hematopoietic cells. Exp Hematol 2002;30:450-459
12. Schwarz RE. Platelet counts and prognosis of pancreatic cancer. Lancet 1999;353:2158-2159
13. Slichter SJ, Harker LA. Hemostasis in malignancy. Ann N Y Acad Sci 1974;230:252-262
14. Tang DG, Honn KV. Adhesion molecules and tumor metastasis: an update. Invasion Metastasis 1994-95;14:109-122
15. Honn KV, Tang GT, Chen YQ. Platelets and cancer metastasis: more than an epiphenomenon. Semin Thromb Hemost 1992;18:392-415
16. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nat Med 1995;1:27-31
17. Wojtukiewicz MZ, Sierko E, Klement P, Rak J. The hemostatic system and angiogenesis in malignancy. Neoplasia 2001;3:371-384
18. Wojtukiewicz MZ, Sierko E, Rak J. Contribution of the hemostatic system to angiogenesis in cancer. Semin Thromb Hemost 2004;30:5-20
19. Timår J, To̊wåri J, Råso̊ E, Mèszåros L. Platelet-mimicry of cancer cells: epiphenomenon with clinical significance. Oncology 2005;69:185-201
20. Heemskerk JWM, Bevers EM, Lindhout T. Platelet activation and blood coagulation. Thromb Haemost 2002; 88:186-193
21. Andrews RK, Shen Y, Gardiner EE, Berndt MC. Platelet adhesion receptors and (patho)physiological thrombus formation. Histol Histopathol 2001;16:969-980
22. Chen H, Locke D, Liu Y, Kahn ML. The platelet receptor GPVI mediates both adhesion and signaling responses to collagen in a receptor density-dependent fashion. J Biol Chem 2002;277:3011-3019
23. Kamata T, Takada Y. Platelet integrin alphaIIbbeta3-ligand interactions: what we learn from the structure? Int J Hematol 2001;74:382-389
24. Coughlin SR. Protease-activated receptors and platelet function. Thromb Haemost 1999;82:353-356
25. Di Virgilio F, Chiozzi P, Ferrari D, et al. Nucleotide receptors: an emerging family of regulatory molecules in blood cells. Blood 2001;97:587-600
26. Rendu F, Brohard-Bohn B. The platelet release reaction: granules' constituents, secretion and functions. Platelets 2001;12:261-273
27. Wehmeier A, Tschope D, Esser J, et al. Circulating activated platelets in myeloproliferative disorders. Thromb Res 1991;61:271-278
28. Blann AD, Gurney M, Wadley D, Bareford D, Stonelake P, Lip GY. Increased soluble P-selectin in patients with hematological and breast cancer: a comparison with fibrinogen, plasminogen activator inhibitor and von Willebrand factor. Blood Coagul Fibrinolysis 2001;12:43-50
29. Caine GJ, Lip GY, Stonelake PS, Ryan P, Blann AD. Platelet activation, coagulation and angiogenesis in breast and prostate carcinoma. Thromb Haemost 2004;92:185-190
30. Karpatkin S, Nierodzik ML, Klepfish A. Role of platelets, thrombin in cancer. Vessels 1996;2:17-23
31. Falanga A, Rickles FR. Pathophysiology of the thrombophilic state in the cancer patient. Semin Thromb Hemost 1999;25:173-182
32. Yu JL, Rak JW. Shedding of tissue factor (TF)-containing microparticles rather than alternatively spliced TF is the mein source of TF activity released from human cancer cells. J Thromb Haemost 2004;2:2065-2067
33. Nomura S, Fukuhara S. Platelet microparticles. Methods Mol Biol 2004;272:269-277
34. Kitagawa H, Yamamoto N, Yamamoto K, et al. Involvement of platelet membrane glycoprotein Ib and glycoprotein IIb/IIIa complex in thrombin-dependent and -independent platelet aggregations induced by tumor cells. Cancer Res 1989;49:537-541
35. Hejna M, Raderer M, Zielinsky CC. Inhibition of metastasis by anticoagulants. J Natl Cancer Inst 1999;91:22-36
36. Gasic GJ, Gasic TB, Steward CC. Antimetastatic effects associated with platelet reduction. Proc Natl Acad Sci USA 1968;61:46-52
37. Nierodzik ML, Klepfish A, Karpatkin S. Role of platelets, thrombin, integrin IIb-IIIa, fibronectin and von Willebrand factor on tumor adhesion in vitro and metastasis in vivo. Thromb Haemost 1995;74:282-290
38. McCarty OJ, Mouse SA, Bray PF, Konstantopoulos K. Immobilized platelets support human colon carcinoma cell tethering, rolling, and firm adhesion under dynamic flow conditions. Blood 2000;96:1789-1797
39. Felding-Habermann B. Tumor cell-platelet interaction in metastatic disease. Haemostasis 2000;31(Suppl 1):55-58
40. Chopra H, Timar J, Rong X, et al. Is there a role for the tumor cell integrin αIIbβ3 in tumor-cell induced platelet aggregation. Clin Exp Metastasis 1992;10:125-137
41. Steinert BW, Tang DG, Grossi IM, Umbarger LA, Honn KV. Studies on the role of platelet eicosanoid metabolism and integrin αIIbβ3 in tumor-cell-induced platelet aggregation. Int J Cancer 1993;54:92-101
42. Lip GYH, Chin BSP, Blann AD. Cancer and the prothrombotic state. Lancet Oncol 2002;3:27-34
43. Nash GF, Turner LF, Schully MF, Kakkar AK. Platelets and cancer. Lancet Oncol 2002;3:425-430
44. Pasqualini ME, Mohn CE, Petiti JP, Manzo P, Eynard AR. COX and LOX eicosanoids modulate platelet activation and procoagulation induced by two murine cancer cells. Prostaglandins Leukot Essent Fatty Acids 2000;63:377-383
45. Boucharaba A, Serre C-M, Grès S, et al. Platelet-derived lysophosphatic acid supports the progression of osteolytic bone metastases in breast cancer. J Clin Invest 2004;114: 1714-1725
46. Belloc C, Lu H, Soria C, et al. The effect of platelets on invasiveness and protease production of human mammary tumor cells. Int J Cancer 1995;60:413-417
47. Verheul HMW, Hoekman K, Lupu F, et al. Platelet and coagulation activation with vascular endothelial growth factor generation in soft tissue sarcomas. Clin Cancer Res 2000;6:166-171
48. Ischii L, Fukushima N, Ye X, Chun J. Lysophospholipid receptors: signaling and biology. Annu Rev Biochem 2004; 73:321-354
49. Van Corven EJ, Groenink A, Jalink K, Eicholtz T, Moolenaar WH. Lysophosphatidate-induced cell proliferation: identification and dissection of signaling pathways mediated by G proteins. Cell 1989;59:45-54
50. Möhle R, Green D, Moore MA, Nachman RL, Rafii S. Constitutive production and thrombin-induced relaease of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci USA 1997;94:663-668
51. Salgado R, Vermeulen PB, Benoy I, et al. Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients. Br J Cancer 1999; 80:892-897
52. Verheul HMW, Hoekman K, Luykx-de Bakker S, et al. Platelet transporter of vascular endothelial growth factor. Clin Cancer Res 1997;3:2187-2190
53. Wartiovaara U, Salven P, Mikkola Heta I. Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation. Thromb Haemost 1998;80:171-175
54. Ohm JE, Carbone DP. VEGF as a mediator of tumor-associated immunodeficiency. Immunol Res 2001;23:263-272
55. Yang L, Carbone DP. Tumor-host immune interactions and dendritic cell dysfunction. Adv Cancer Res 2004;92:13-27
56. Nieswandt B, Hafner M, Echtenacher B, Männel DN. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res 1999;59:1295-1300
57. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-1186
58. Verheul HM, Jorna AS, Hoekman K, et al. Vascular endothelial growth factor-stimulated endothelial cells promote adhesion and activation of platelets. Blood 2000;96: 4216-4221
59. Pipili-Synetos E, Papadimitriou E, Maragoudakis ME. Evidence that platelets promote tube formation by endothelial cells on matrigel. Br J Pharmacol 1998;125:1252-1257
60. Kisucka J, Butterfield CE, Duda DG, et al. Platelets and platelet adhesion support angiogenesis while preventing excessive hemorrhage. Proc Natl Acad Sci USA 2006; 103:855-860
61. Rhee JS, Black M, Schubert U, et al. The functional role of blood platelet components in angiogenesis. Thromb Haemost 2004;92:394-402
62. Brill A, Dashevsky O, Rivo J, Gozal Y, Varon D. Platelet-derived microparticles induce angiogenesis and stimmulate post-ischaemic revascularization. Cardiovasc Res 2005;67:30-38
63. McDowell G, Temple I, Li C, et al. Alteration in platelet function in patients with early breast cancer. Anticancer Res 2005;25:3963-3966
64. Werther K, Chjritensen IJ, Nielsen HJ. Determination of vascular endothelial growth factor (VEGF) in circulating blood: significance of VEGF in various leucocytes and platelets. Scand J Clin Lab Invest 2002;62:343-350
65. Kim SJ, Choi IK, Park KH, et al. Serum vascular endothelial growth factor per platelet count in hepatocellular carcinoma: correlations with clinical parameters and survival. Jpn J Clin Oncol 2004;34:184-190
66. Ma L, Perini R, McKnight W, Klein A, Hollenberg MD, Wallace JL. Proteinase-activated receptors 1 and 4 counter-regulate endostatin and VEGF release from human platelets. Proc Natl Acad Sci USA 2005;102:216-220
67. Brock TA, Dvorak HF, Senger DR. Tumour secreted vascular permeability factor increases cytosolic Ca2+ and von Willebrand factor release in human cells. Am J Pathol 1991;138:213-221
68. Thurston G, Rudge JS, Ioffe E, et al. Angiopoietin-1 protects the adult vasculature against leakage. Nat Med 2000;6:460-463
69. Clauss M, Gerlach M, Gerlach H, et al. Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med 1990;172:1535-1545
70. Friesel R, Maciag T. Fibroblast growth factor prototype release and fibroblast growth factor receptor signaling. Thromb Haemost 1999;82:748-754
71. Valter MM, Wietler OD, Pietsche T, Pietsch T. Differential control of VEGF synthesis and secretion in human glioma cells by IL-1 and EGF. Int J Dev Neurosci 1999; 17:565-577
72. Guo P, Gu W, Xu L, et al. Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment. Am J Pathol 2003; 162:1083-1093
73. Tomita N, Morishita R, Taniyama Y, et al. Angiogenic property of hepatocyte growth factor is dependent on upregulation of essential transcription factor for angiogenesis ets-1. Circulation 2003;107:1411-1417
74. Lee OH, Bae SK, Bae MH, et al. Identification of angiogenic properties of insulin-like growth factor II in in vitro angiogenesis models. Br J Cancer 2000;82:385-391
75. Dunn SE, Tores JV, Nihei N, Barrett JC. The insulin growth factor-1 elevates urokinase-type plasminogen activator-1 in human breast cancer cells: a new avenue for breast cancer therapy. Mol Carcinog 2000;27:10-17
76. Breier G, Blum S, Peli J, et al. Transforming growth factor-beta and Ras regulate the VEGF/VEGF-receptor system during tumor angiogenesis. Int J Cancer 2002;97:142-148
77. Davis S, Yancopoulos GD. Yin and yang in angiogenesis. Curr Top Microbiol Immunol 1999;237:173-185
78. McMahon GA, Petitclerc E, Stefansson S, et al. Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis. J Biol Chem 2001;276:33964-33968
79. VanWijk MJ, VanBavel E, Sturk A, Nieuwland R. Microparticles in cardiovascular diseases. Cardiovasc Res 2003;59: 277-287
80. Teuscher E, Weidlich V. Adenosine nucleotides, adenosine and adenine as angiogenesis factors. Biomed Biochim Acta 1985;44:493-495
81. English D, Welch Z, Kovala AT, et al. Sphingosine 1-phosphate released from platelets during clotting accounts for the potent endothelial cell chemotactic activity of blood serum and provides a novel link between hemostasis and angiogenesis. FASEB J 2000;14:2255-2265
82. Freyssinet JM. Cellular microparticles: what are they bad or good for? J Thromb Haemost 2003;1:1655-1662
83. Janowska-Wieczorek A, Wysoczynski M, Kijowski J, et al. Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer. Int J Cancer 2005; 113:752-760
84. Good DJ, Polverini PJ, Rastinejad F, et al. A tumor supprressor-dependent inhibitor of angiogenesis is immunologically and functionally indistiguishable from a fragment of thrombospondin. Proc Natl Acad Sci USA 1990; 87:6624-6628
85. Taylor S, Folkman J. Protamine is an inhibitor of angiogenesis. Nature 1982;297:307-312
86. Nakabayashi M, Morishita R, Nakagami H, et al. HGF/NK4 inhibited VEGF-induced angiogenesis in in vitro cultured endothelial cells and in vivo rabbit model. Diabetologia 2003;46:115-123
87. Pizurki L, Zhou Z, Glynos K, Roussos C, Papapetropoulos A. Angiopoietin-1 inhibits endothelial permeability, neutrophil adherence and IL-8 production. Br J Pharmacol 2003;139:329-336
88. Jurasz P, Santos-Martinez MJ, Radomska A, Radomski MW. Generation of platelet angiostatin mediated by urokinase plasminogen activator: effects on angiogenesis. J Thromb Haemost 2006;4:1095-1106
89. Sawicki G, Salas E, Murat J, et al. Release of gelatinase A during platelet activation mediates aggregation. Nature 1997; 386:616-619
90. Menashi S, He L, Soria C, et al. Modulation of endothelial cells fibrinolytic activity by platelets. Thromb Haemost 1991; 65:77-81
91. Huang S, Van Arsdall M, Tedjarati S, et al. Contribution of stromal metalloproteinase 9 to angiogenesis and growth of human ovarian carcinoma in mice. J Natl Cancer Inst 2002; 94:1134-1142
92. Kazes I, Elalamy I, Sraer JD, et al. Platelet release of trimolecular complex components MT1-TIMP2-MMP2: involvement in MMP2 activation and platelet aggregation. Blood 2000;96:3064-3069
93. Vlodavsky I, Eldor A, Haimovitz-Friedman A, et al. Expression of heparanase by platelets and circulating cells of the immune system: possible involvement in diapedesis and extravasation. Invasion Metastasis 1992;12:112-127
94. Coller BS, Peerschke EL, Scudder LE, Sullivan CA. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombastenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J Clin Invest 1983;72:325-328
95. Coller BS. Anti-GpIIb/IIIa drugs: current strategies and future directions. Thromb Haemost 2001;86:427-443
96. Trikha M, Zhou Z, Timar J, et al. Multiple roles for platelet GPIIb/IIa and platelet alpha v beta 3 integrins in tumor growth, angiogenesis, and metastasis. Cancer Res 2002;62: 2824-2833
97. Amirkhosravi A, Amaya M, Siddiqui F, et al. Blockade of GpIIb/IIIa inhibits the release of vascular endothelial growth factor (VEGF) from tumor-cell-activated platelets and experimental metastasis. Platelets 1999;10:285-292
98. 2 inhibit β3 integrin mediated tumor growh and angiogenesis. [abstract] Proc Am Assoc Cancer Res 2000;42:824
99. Engelberg H. Actions of heparins that may affect the malignant process. Cancer 1999;85:257-272
100. Amirkhosravi A, Mousa SA, Amaya M, et al. Inhibition of tumor cell-induced platelet aggregation and lung metastasis by the oral GpIIb-IIIa antagonist XV454. Thromb Haemost 2003;90:549-554
101. Sheu JR, Lin CH, Chung JI, Teng CM, Huang TF. Triflavin, an Arg-Gly-Asp containing snake venom peptide, inhibits aggregation of human platelets induced by human hepatoma cell line. Thromb Res 1992;66:679-691
102. Chiang HS, Swaim MW, Huang TF. Characterization of platelet aggregation induced by human colon adenocarcinoma cells and its inhibition by snake venom peptides, trigramin and rhodostomin. BrJ Haematol 1994;87:325-331
103. Chiang HS, Swaim MW, Huang TF. The Arg-Gly-Asp-containing peptide, rhodostomin, inhibits in vitro cell adhesion to extracellular matrices and platelet aggregation caused by saos-2 human osteosarcoma cells. Br J Cancer 1995;71:265-270
104. Chiang HS, Swaim MW, Huang TF. Characterization of platelet aggregation induced by human breast carcinoma and its inhibition by snake venom peptides, trigramin and rhodostomin. Breast Cancer Res Treat 1995;33:225-235
105. Lever R, Page CP. Novel drug development opportunities for heparin. Nat Rev Drug Discov 2002;1:140-148
106. da Silva MS, Horton JA, Wijelath JM, et al. Heparin modulates integrin-mediated cellular adhesion: specificity of interaction with alpha and beta integrin subunits. Cell Adhes Commun 2003;10:59-67
107. Borsig L, Wong R, Feramisco J, et al. Heparin and cancer revised: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci USA 2001;98:3352-3357
108. Ludwig RJ, Beohme B, Podda M, et al. Endothelial P-selectin as a target of heparinb action in experimental melanoma lung metastasis. Cancer Res 2004;64:2743-2750
109. Kakkar AK. Low molecular weight heparin and survival in cancer. Haematological Rep 2005;1:27
110. Butenas S, Cawthern K, Veer C, et al. Antiplatelet agents in tissue factor-induced blood coagulation. Blood 2001;97: 2314-2322
111. Waltermann A, Wolzt M, Petersmann K, et al. Large amounts of vascular endothelial growth factor at the site of hemostatic plug formation in vivo. Arterioscler Thromb Vasc Biol 1999;19:1757-1760
112. Gasic GJ, Gasic TB, Stewart CC. Antimetastatic effect associated with platelet reduction. Proc Natl Acad Sci USA 1968;61:46-52
113. Sheu JR, Lin CH, Pung HC, Teng CM, Huang TF. Triflavin, an Arg-Gly-Asp-containing peptide, inhibits tumor cell-induced platelet aggregation. Jpn J Cancer Res 1993;84:1062-1071
114. Damiano BP, Derian CK, Maryanoff BE, Zhang HC, Gordon PA. RWJ-58259: a selective antagonists of protease activated receptor-1. Cardiovasc Drug Rev 2003;21:313-326
115. Shi X, Gangedharan B, Brass LF, Ruf W, Mueller BM. Protease-activated receptors (PAR-1 and PAR-2) contribute to tumor cell motility and metastasis. Mol Cancer Res 2004;2:395-402
116. Zania P, Kritikou S, Flordellis CS, Maragoudakis ME, Tsopanoglou NE. Blockage of angiogenesis by small molecule antagonists to protease-activated receptor-1: association with endothelial cell growth suppression and induction of apoptosis. J Pharmacol Exp Ther 2006;318: 246-254
117. Nash GF, Walsh DC, Kakkar AK. The role of the coagulation system in tumour angiogemesis. Lancet Oncol 2001;2:608-613
118. Nigam S, Zakrzewic A, Eskafi S, Roscher A. Clinical significance of prostacyclin and thromboxane in cancer of the female breast and genital tract. Cancer Metastasis Rev 1992;11:411-420
119. Nie D, Che M, Zacharek A, et al. Differential expression of thromboxane synthase in prostate carcinoma: role in tumor cell motility. Am J Pathol 2004;164:429-439
120. Honn KV, Tang DG, Butovich IA, Liu B, Timar J, Hagmann W. 12-lipooxygenases and 12(S)-HETE: role in cancer metastasis. Cancer Metastasis Rev 1994;13:365-366
121. Tang DG, Li L, Zhu Z, et al. BMD188, a novel hydroxamic acid compound, demonstrates potent an prostate cancer effects in vitro and in vivo by inducing apoptosis: requirements for mitochondria, reactive oxygen species, and proteases. Pathol Oncol Res 1998;4:179-190
122. Gasic GJ, Gasic TB, Galanti N, Johnson T, Murphy S. Platelet tumor interactions in mice. The role of platelets in spread of malignant diseases. Int J Cancer 1973;11:704-718
123. Wood S Jr, Hilgard P. Aspirin and tumor metastasis. Lancet 1972;2:1416-1417
124. Mamytbeková A, Rezábek K, Kacerovská H, Grimová J, Svobodová J. Antimetastatic effect of flurbiprofen and other platelet aggregation inhibitors. Neoplasma 1986;33:417-421
125. Mehta P, Lawson D, Ward MB, Lee-Ambrose L, Kimura A. Effect of tromboxane A2 inhibition on osteogenic sarcoma cell-induced platelet aggregation. Cancer Res 1986; 46:5061-5063
126. Bando H, Yamashita T, Tsubura E. Effects of antiplatelet agents on pulmonary metastases. Gann 1984;75:284-291
127. Mussoni L, Poggi A, De Gaetano G, Donati MB. Effect of diltazole, an inhibitor of platelet aggregation, on a metastasizing tumor in mice. Br J Cancer 1978;37:126-129
128. Hilgard P, Heller H, Schmidt CG. The influence of platelet aggregation inhibitors on metastasis formation in mice (3LL). Z Krebsforsch Klin Onkol Cancer Res Clin Oncol 1976;86:243-250
129. Lichtner RB, Hutchinson G, Wedderburn N, Hellmann K. Antiplatelet pyrimido-pyrimidines and metastasis. Cancer Treat Rev 1985;12:221-234
130. Lichtner RB, Hutchinson G, Hellmann K. The pyrimidopyrimidines derivatives RA233 and RX-RA85 affect cell cycle distribution of two murine tumour cell lines. Eur J Cancer Clin Oncol 1989;25:945-951
131. Stackpole CW, Fornabaio DM, Alterman AL. Failure of orally administered RA233 to influence B16 melanoma growth or metastasis. Clin Exp Metastasis 1987;5:165-180
132. Li XT, Hellmann K. Effect of DRA233 alone and combined with radiation on experimental tumour metastasis. Part 1. Clin Exp Metastasis 1983;1:51-59
133. Gastpar H. Modification of metastasis formation by inhibition of platelet aggregation. Experimental and clinical results. Laryngol Rhinol Otol (Stuttg) 1983;62:578-585
134. Kohga S, Kinjo M, Tanaka K, Ogawa H, Ishihara M, Tanaka N. Effects of 5-(2-chlorobenzyl)-4,5,6,7,-tetrahydrothieno[3,2-C]pyridine hydrochloride (ticlopidine), a platelet aggregation inhibitor, on blood-borne metastasis. Cancer Res 1981;41:4710-4714
135. Fabra A, de Castellamau C, Carretero F, Martinez E, Sancho MJ, Rutilant ML. Effects of ticlopidine on metastasis production in mice bearing Lewis lung carcinoma. Invasion Metastasis 1987;7:53-60